Information Provided By:
Fly News Breaks for April 12, 2019
XNCR
Apr 12, 2019 | 06:22 EDT
Guggenheim analyst Michael Schmidt started Xencor with a Buy rating and $42 price target. The company has a "deep" clinical pipeline of bispecific T-cell engagers and dual checkpoint / co-stimulatory antibodies with early clinical data readouts through the second half of 2019 that represent potential upside, Schmidt tells investors in a research note.
News For XNCR From the Last 2 Days
There are no results for your query XNCR